https://www.fiercebiotech.com/biotech/phase-2-bowel-disease-data-fires-prometheus-stock-170-and-sets-bar-pfizer-and-roivant
参考文献: [1]. Tulisokibart. IMGT/mAb-DB. [2]. Feagan B G, Sands B, Siegel C A, et al. DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results[J]. Journal of Crohn's and Colitis, 2023, 17(Supplement_1): i162...
Prometheus Biosciences, Inc today announced it has enrolled its first patient in the ATHENA-SSc-ILD trial, a placebo-controlled and statistically powered Phase 2 study of PRA023 in SSc-ILD. - First therapeutic candidate for the treatment ...
12月17日Sanofi和Teva公布了合作开发的Duvakitug(TEV-574)的Phase 2b初步结果,这是一项代号RELIEVE UCCD的试验(NCT05499130),共入组了UC和CD患者各约120例,按1:1:1分配到高低剂量组和安慰剂组。 网页链接 乍一看14周诱导期的主要临床终点,感觉确实非常炸裂:UC部分,高剂量组的临床缓解率居然高达47.8%,断崖式领...
同型:Human IgG1 kappa 推荐同型对照抗体:Human IgG1 kappa, Isotype Control 参考文献: [1]. Tulisokibart. IMGT/mAb-DB. [2]. Feagan B G, Sands B, Siegel C A, et al. DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Res...
[1]. Tulisokibart. IMGT/mAb-DB. [2]. Feagan B G, Sands B, Siegel C A, et al. DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results[J]. Journal of Crohn's and Colitis, 2023, 17(Supplement_1): i162-i164. ...